Momenta Pharmaceuticals Inc (MNTA): Bennett M Shapiro , director of Momenta Pharmaceuticals Inc sold 5,200 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $13.00 per share for a total value of $67,600.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 23, 2016, Craig A Wheeler (President) sold 5,880 shares at $10.18 per share price.On May 23, 2016, Bruce Leicher (SVP & General Counsel) sold 1,000 shares at $10.40 per share price.Also, On May 23, 2016, James M. Roach (Senior VP, Development and Chi) sold 1,092 shares at $10.17 per share price.On May 23, 2016, Ganesh Venkataraman Kaundinya (Senior V.P., Research) sold 1,050 shares at $10.17 per share price.
Shares of Momenta Pharmaceuticals (MNTA) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.11 points or -0.90% at $12.13 with 4,30,737 shares getting traded. Post opening the session at $12.11, the shares hit an intraday low of $11.88 and an intraday high of $12.33 and the price vacillated in this range throughout the day. The company has a market cap of $843 M and the number of outstanding shares has been calculated to be 6,94,96,190 shares. The 52-week high of Momenta Pharmaceuticals is $25.56 and the 52-week low is $7.86.
Company has been under the radar of several Street Analysts.Momenta Pharmaceuticals is Initiated by Goldman to Neutral and the brokerage firm has set the Price Target at $14. The Rating was issued on Jun 6, 2016.
Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Companys product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.